EP
IRWD icon

Edgestream Partners’s Ironwood Pharmaceuticals IRWD Stock Holding History

Edgestream Partners’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-296,287
Closed -$2.58M – 941
2024
Q1 		$2.58M Buy
+296,287
New +$3.6M 0.13% 275
2023
Q4 		– Sell
-48,528
Closed -$467K – 946
2023
Q3 		$467K Sell
48,528
-9,139
-16% -$89.6K 0.04% 604
2023
Q2 		$614K Buy
+57,667
New +$620K 0.06% 482

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Edgestream Partners's IRWD Position: Q2 2024 in Review

Edgestream Partners sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2024, closing a stake of 296,287 shares — an estimated $2.58M sold.

Edgestream Partners first reported a position in IRWD in Q2 2023 and held it in 3 quarters. The position peaked at $2.58M in Q1 2024. 226 funds tracked by Wall St. Rank hold IRWD as of Q2 2024.

  • Edgestream Partners reported no remaining Ironwood Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Edgestream Partners sold 296,287 Ironwood Pharmaceuticals shares in Q2 2024, an estimated $2.58M.
  • Edgestream Partners first reported a position in Ironwood Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Edgestream Partners's Ironwood Pharmaceuticals position peaked at $2.58M in Q1 2024.
  • 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2024.

Based on Edgestream Partners's 13F filing for Q2 2024, filed 9 Aug 2024.